My Portfolio

GSK plc GSK-GB:London Stock Exchange

RT Quote | Exchange | GBp

Last | 11:36 AM BST

1,851.50

+31.00 (+1.70%)

52 week range

1,315.00 - 2,282.00

Open1,817.50
Day High1,856.50
Day Low1,813.00
Prev Close1,820.50
52 Week High2,282.00
52 Week High Date02/18/26
52 Week Low1,315.00
52 Week Low Date07/18/25

Latest On GSK plc

Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to knowMay 27, 2026CNBC.com
Lilly buys trio of vaccine makersMay 26, 2026CNBC.com
How investors are trading the UK as political turmoil rattles British marketsMay 21, 2026CNBC.com
Bristol Myers Squibb turns to China to develop new drugsMay 15, 2026CNBC.com
FDA withdrew studies finding Covid and shingles vaccines were safeMay 5, 2026CNBC.com
UK's biggest drugmakers see profit bump, as pharma grapples with U.S. policiesApril 29, 2026CNBC.com
Trump tariff fallout: Industries grapple with lingering effects one year laterApril 3, 2026CNBC.com
Novartis to pay $2 billion for Excellergy, in second multi-billion dollar deal in a weekMarch 27, 2026CNBC.com
Pfizer to seek approval for Lyme disease vaccine candidate despite trial missMarch 23, 2026CNBC.com
FDA approves leucovorin as first drug for rare genetic disorderMarch 10, 2026CNBC.com

Key Stats

Market Cap75.014B
Shares Out4.05B
10 Day Average Volume6.08M
Dividend67.00
Dividend Yield3.62%
Beta0.81

Latest On GSK plc

Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to knowMay 27, 2026CNBC.com
Lilly buys trio of vaccine makersMay 26, 2026CNBC.com
How investors are trading the UK as political turmoil rattles British marketsMay 21, 2026CNBC.com
Bristol Myers Squibb turns to China to develop new drugsMay 15, 2026CNBC.com
FDA withdrew studies finding Covid and shingles vaccines were safeMay 5, 2026CNBC.com
UK's biggest drugmakers see profit bump, as pharma grapples with U.S. policiesApril 29, 2026CNBC.com
Trump tariff fallout: Industries grapple with lingering effects one year laterApril 3, 2026CNBC.com
Novartis to pay $2 billion for Excellergy, in second multi-billion dollar deal in a weekMarch 27, 2026CNBC.com
Pfizer to seek approval for Lyme disease vaccine candidate despite trial missMarch 23, 2026CNBC.com
FDA approves leucovorin as first drug for rare genetic disorderMarch 10, 2026CNBC.com

KEY STATS

Open1,817.50
Day High1,856.50
Day Low1,813.00
Prev Close1,820.50
52 Week High2,282.00
52 Week High Date02/18/26
52 Week Low1,315.00
52 Week Low Date07/18/25
Market Cap75.014B
Shares Out4.05B
10 Day Average Volume6.08M
Dividend67.00
Dividend Yield3.62%
Beta0.81

RATIOS/PROFITABILITY

EPS (TTM)144.43
P/E (TTM)12.82
Fwd P/E (NTM)-
EBITDA (TTM)12.438B
ROE (TTM)36.42%
Revenue (TTM)32.78B
Gross Margin (TTM)72.94%
Net Margin (TTM)19.39%
Debt To Equity (MRQ)106.74%

EVENTS

Earnings Date-
Ex Div Date05/14/2026
Div Amount0.17
Split Date-
Split Factor-

Content From Our Affiliates

GlaxoSmithKline (GSK) Gets a Buy from Jefferies1 Hour AgoTipRanks
FDA issues draft guidance to help accelerated cell, gene therapies for patientsJune 2, 2026TipRanks
Deutsche Bank Remains a Hold on GlaxoSmithKline (GSK)June 2, 2026TipRanks
GSK boosts treasury stock as buyback lifts voting share baseJune 1, 2026TipRanks
GSK Updates Market on Total Voting Rights and Share CapitalJune 1, 2026TipRanks

Profile

GSK plc is a United Kingdom-based biopharma company. The Company’s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases...

Jonathan Symonds CBE

Independent Non-Executive Chairman of the Board

Luke Miels

Chief Executive Officer, Executive Director

Julie Brown

Chief Financial Officer, Executive Director

Address

980 Great West Road

Brentford

TW8 9GS

United Kingdom

https://www.gsk.com/